Ishita Drugs

Why is Ishita Drugs & Industries Ltd falling/rising?

As of 04-Sep, Ishita Drugs & Industries Ltd's stock price has risen to Rs 72.90, up 2.85%, driven by strong opening gains, increased investor participation, and outperformance against its sector. Despite recent declines, current trading dynamics suggest a potential recovery phase.

As of 04-Sep, Ishita Drugs & Industries Ltd is experiencing a rise in its stock price, currently at Rs 72.90, reflecting an increase of 2.02 (2.85%). This upward movement can be attributed to several factors observed in today's trading activity. Notably, the stock opened with a significant gain of 4.12% and reached an intraday high of Rs 73.8. Additionally, the stock has outperformed its sector by 3.3%, indicating stronger performance relative to its peers.<BR><BR>Another contributing factor to the stock's rise is the notable increase in investor participation, with delivery volume on 03 Sep rising by 678.75% compared to the 5-day average. This surge in trading activity suggests heightened interest from investors, which can positively influence stock prices.<BR><BR>Despite some recent underperformance over longer periods, such as a 6.27% decline over the past month, the current trading dynamics, including erratic trading patterns and the stock's position relative to moving averages, indicate a potential recovery phase. Overall, the combination of strong opening gains, increased investor engagement, and sector outperformance are key reasons for the rise in Ishita Drugs & Industries Ltd's stock price.

Which are the latest news on Ishita Drugs?

Who are in the management team of Ishita Drugs?

The management team of Ishita Drugs includes Jagdish Agrawal (Managing Director), Govind Gupta, Niranjan Agrawal, and Arvind Sapkal (Directors), along with Abha Agrawal (Non-Executive Director).

The management team of Ishita Drugs includes the following individuals:<BR><BR>1. Jagdish Agrawal - Managing Director<BR>2. Govind Gupta - Director<BR>3. Abha Agrawal - Non-Executive Director<BR>4. Niranjan Agrawal - Director<BR>5. Arvind Sapkal - Director<BR><BR>If you need more details about their roles or the company, feel free to ask!

What does Ishita Drugs do?

Ishita Drugs & Industries Ltd manufactures Active Pharmaceutical Ingredients, drug intermediates, fine chemicals, and excipients. As of June 2026, it reported net sales of 3 Cr and a market cap of INR 22 Cr.

Overview:<BR>Ishita Drugs & Industries Ltd is engaged in the manufacture of various Active Pharmaceutical Ingredients, drug intermediates, fine chemicals, and excipients within the Pharmaceuticals & Biotechnology industry, categorized as a Micro Cap company.<BR><BR>History:<BR>Ishita Drugs & Industries Ltd was incorporated in February 1992 by Jagdish Agarwal. The latest quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 3 Cr (Quarterly Results - Jun 2026)<BR>- Net Profit: 0 Cr (Quarterly Results - Jun 2026)<BR>- Market Cap: INR 22 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 31.00<BR>- Industry P/E: 37<BR>- Dividend Yield: 0.00%<BR>- Debt-Equity: -0.41<BR>- Return on Equity: 6.58%<BR>- Price to Book: 2.05<BR><BR>Contact Details:<BR>Address: Survey No 179/1 Taluka Sanand, Village Vasna-Iyava Ahmedabad Gujarat : 382170<BR>Email: ishitadrugs@vsnl.net<BR>Website: http://www.ishitadrugs.com

Who are the peers of the Ishita Drugs?

Ishita Drugs' peers include Guj. Terce Labs, Medi Caps, Cian Healthcare, Welcure Drugs, Venmax Drugs, Centuple Global, Shree Ganesh Bio, Colinz Labs, and Bacil Pharma. Cian Healthcare leads in 1-year returns at 252.28%, while Ishita Drugs has a return of -3.20%.

Peers: The peers of Ishita Drugs are Guj. Terce Labs., Medi Caps, Cian Healthcare, Welcure Drugs, Venmax Drugs, Centuple Global, Shree Ganesh Bio, Colinz Labs, and Bacil Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Centuple Global, while Average management risk is found at Welcure Drugs and Saroja Pharma In, and the rest have Below Average management risk. Good capital structure is noted at Medi Caps, Welcure Drugs, Ishita Drugs, Shree Ganesh Bio, Colinz Labs, and Centuple Global, while Below Average capital structure is seen at Guj. Terce Labs., Cian Healthcare, Venmax Drugs, and the rest. Average growth is exhibited by Guj. Terce Labs. and Venmax Drugs, while Below Average growth is found at Medi Caps, Cian Healthcare, Welcure Drugs, Ishita Drugs, Shree Ganesh Bio, and the rest.<BR><BR>Return Snapshot: Cian Healthcare has the highest 1-year return at 252.28%, while Welcure Drugs has the lowest at -72.73%. Ishita Drugs' 1-year return of -3.20% is better than that of Welcure Drugs but worse than Cian Healthcare. Additionally, several peers, including Welcure Drugs, Venmax Drugs, and Shree Ganesh Bio, have negative six-month returns.

How big is Ishita Drugs?

As of 31st August, Ishita Drugs & Industries Ltd has a market capitalization of 22.00 Cr, with recent net sales of 12.42 Cr and a net profit of 0.71 Cr. The company reported shareholder's funds of 10.79 Cr and total assets of 16.30 Cr for the annual period ending in March 2025.

As of 31st August, Ishita Drugs & Industries Ltd has a market capitalization of 22.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Ishita Drugs reported Net Sales of 12.42 Cr and a Net Profit of 0.71 Cr.<BR><BR>For the latest annual period ending in March 2025, the company had Shareholder's Funds of 10.79 Cr and Total Assets amounting to 16.30 Cr.

Should I buy, sell or hold Ishita Drugs & Industries Ltd?

Are Ishita Drugs & Industries Ltd latest results good or bad?

Ishita Drugs & Industries Ltd's latest results are largely negative, showing a 37.93% year-on-year decline in net profit and a 32.89% drop in net sales, leading to a 6.77% decrease in stock price post-announcement. While there are some positive aspects, such as a debt-free balance sheet, the overall performance raises concerns about the company's future prospects.

Ishita Drugs & Industries Ltd's latest results present a mixed picture, leaning more towards negative. In Q4 FY26, the company reported a net profit of ₹0.18 crore, which is a 12.50% increase quarter-on-quarter. However, this represents a significant decline of 37.93% compared to the same quarter last year. <BR><BR>Net sales for the same quarter were ₹3.06 crore, down 2.55% from the previous quarter and a steep 32.89% year-on-year. This ongoing revenue contraction is concerning, especially given the volatility in sales over recent quarters, which has seen significant fluctuations.<BR><BR>Operating margins have also deteriorated, falling to 3.27%, down from 4.46% in the previous quarter and 6.36% a year ago. This decline indicates increasing cost pressures that the company is struggling to manage.<BR><BR>Despite a debt-free balance sheet and a relatively attractive valuation compared to industry peers, the market reacted negatively to these results, with the stock price declining by 6.77% after the announcement. Investors are likely worried about the company's declining revenue trajectory and operational challenges.<BR><BR>Overall, while there are some positive aspects, such as the improvement in profit margins due to other income, the overall performance indicates significant operational headwinds and raises concerns about the company's future prospects.

How has been the historical performance of Ishita Drugs?

Ishita Drugs has shown mixed historical performance, with net sales slightly decreasing to 15.00 Cr in March 2025 but profit metrics improving, including a profit after tax of 0.87 Cr and an EPS of 2.91. However, cash flow from operating activities turned negative at -3.00 Cr, indicating challenges in cash generation.

Answer:<BR>The historical performance of Ishita Drugs shows a mixed trend in its financial metrics over the years.<BR><BR>Breakdown:<BR>Ishita Drugs reported net sales of 15.00 Cr in March 2025, a slight decrease from 15.19 Cr in March 2024, but a notable increase from 12.07 Cr in March 2023. The total operating income mirrored this trend, reaching 15.00 Cr in March 2025. The company's total expenditure, excluding depreciation, was 14.00 Cr in March 2025, down from 14.28 Cr in March 2024, while the operating profit (PBDIT) increased to 1.34 Cr from 1.19 Cr in the previous year. Profit before tax also rose to 1.16 Cr in March 2025, up from 0.99 Cr in March 2024, leading to a profit after tax of 0.87 Cr, compared to 0.75 Cr in the prior year. The earnings per share (EPS) improved to 2.91 in March 2025 from 2.51 in March 2024. On the balance sheet, total assets increased to 16.30 Cr in March 2025 from 10.81 Cr in March 2024, while total liabilities also rose to 16.30 Cr, reflecting a significant increase in short-term borrowings to 3.81 Cr. The cash flow from operating activities showed a negative trend with -3.00 Cr in March 2025, down from 2.00 Cr in March 2024, indicating challenges in cash generation despite the growth in profits.

When is the next results date for Ishita Drugs?

Ishita Drugs will announce its results on 12 August 2025.

Ishita Drugs will declare its results on 12 August 2025.

Is Ishita Drugs overvalued or undervalued?

As of June 2, 2025, Ishita Drugs is considered undervalued with a PE ratio of 24.07 and strong ROCE of 39.71%, outperforming peers like Sun Pharma and Divi's Lab, and has achieved a 1-year return of 23.56%, significantly higher than the Sensex's 7.60%.

As of 2 June 2025, Ishita Drugs has moved from a fair to an attractive valuation grade, indicating a shift in market perception. The company appears to be undervalued, with a PE ratio of 24.07, an EV to EBIT of 16.19, and a ROCE of 39.71%. In comparison to its peers, Ishita Drugs is more favorably positioned than Sun Pharma, which has a PE ratio of 35.25, and Divi's Lab, which shows a PE of 79.33, both of which are considered expensive.<BR><BR>Additionally, while peers like Cipla and Dr. Reddy's Labs have attractive valuations with PE ratios of 22.99 and 19.49 respectively, Ishita Drugs' strong ROCE and competitive PEG ratio of 1.47 suggest it is well-positioned for growth relative to its industry. Recent stock performance has also outpaced the Sensex, with a 1-year return of 23.56% compared to the Sensex's 7.60%, reinforcing the notion that Ishita Drugs is undervalued in the current market context.

What is the technical trend for Ishita Drugs?

As of June 3, 2025, Ishita Drugs shows a mildly bearish trend, with bearish weekly MACD and moving averages, while mixed signals from KST and Bollinger Bands suggest potential for future gains.

As of 3 June 2025, the technical trend for Ishita Drugs has changed from bearish to mildly bearish. The weekly MACD remains bearish, while the monthly MACD is mildly bearish, indicating a lack of strong upward momentum. The daily moving averages are also mildly bearish, reinforcing the current trend. The KST shows a mildly bullish stance on the weekly chart but is mildly bearish on the monthly, suggesting mixed signals. The Bollinger Bands indicate a sideways movement on the weekly timeframe but are bullish on the monthly, which could imply potential for future gains. Overall, the current technical stance is mildly bearish, driven primarily by the bearish MACD and moving averages, with some conflicting signals from the KST and Bollinger Bands.

Who are the top shareholders of the Ishita Drugs?

The top shareholders of Ishita Drugs include Umang Financial Services Limited with 9.94%, and Mahendra Girdharilal Wadhwani, the largest public shareholder at 2.15%. Individual investors hold a combined 46.89%, with no mutual funds or foreign institutional investors involved, and no pledged promoter holdings.

The top shareholders of Ishita Drugs include Umang Financial Services Limited, which holds the highest promoter stake at 9.94%. In terms of public shareholders, Mahendra Girdharilal Wadhwani is the largest, with a holding of 2.15%. Additionally, individual investors collectively hold a significant portion, accounting for 46.89% of the shares. There are no mutual funds or foreign institutional investors currently holding shares in the company, and there are no pledged promoter holdings.

Has Ishita Drugs declared dividend?

No Dividend History Available